Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity

Clinical Cancer Research

Volumn 14, Issue 4, 2008, Pages 1192-1199

  Katsumi, Yoshiki ^a,b   Kuwahara, Yasumichi ^a   Tamura, Shinichi ^a   Kikuchi, Ken ^a   Otabe, Osamu ^a   Tsuchiya, Kunihiko ^a   Iehara, Tomoko ^a   Kuroda, Hiroshi ^a   Hosoi, Hajime ^a   Sugimoto, Tohru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL VIABILITY; CORRELATION COEFFICIENT; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RHABDOID TUMOR;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOID TUMOR;

EID: 39749104203     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1661     Document Type: Article

References (42)

1. Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alteration of the hSNF5/INI1gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002;8:3461-7.
2. Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1in aggressive paediatric cancer. Nature 1998;394:203-6.
3. Tomlinson GE, Breslow NE, Dome J, et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 2005;23:7641-5.
4. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
5. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-30.
6. Tzahar E, Levkowitz G, Karunagaran D, et al. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem 1994;269:25226-33.
7. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
8. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859-66.
9. Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271-9.
10. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER-2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: aphase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90.
11. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
12. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001;61:2420-3.
13. Spiridon CI, Ghetie MA, Uhr J, et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002;8:1720-30.
14. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:4898-904.
15. Warburton C, Dragowska WH, Gelmon K, et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 2004;10:2512-24.
16. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
17. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-9.
18. Siapati KE, Barker S, Kinnon C, et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 2003;88:1641-8.
19. Melguizo C, Prados J, Marchal JA, et al. Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells. Neoplasia 2003;50:91-6.
20. Staege MS, Hansen G, Baersch G, Burdach S. Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy. Pediatr Blood Cancer 2004;43:23-34.
21. Nakashima Y, Deie M, Yanada S, Sharman P, Ochi M. Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells. Int J Oncol 2005;27:965-71.
22. Sugimoto T, Hosoi H, Horii Y, et al. Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes. Int J Cancer 1999;82:678-86.
23. Mori T, Fukuda Y, Kuroda H, et al. Cloning and characterization of a novel Rab-family gene, Rab36, within the region at 22q11.2 that is homozygously deleted in malignant rhabdoid tumors. Biochem Biophys Res Commun 1999;254:594-600.
24. Misawa A, Hosoi H, Imoto I, Iehara T, Sugimoto T, Inazawa J. Translocation (1+22)(p36;q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor. J Hum Genet 2004;49:586-9.
25. Kuroda H, Moritake H, Sawada K, et al. Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1and p16. Cancer Genet Cytogenet 2005;158:172-9.
26. Kuwahara Y, Hosoi H, Osone S, et al. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res 2004;10:5940-8.
27. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;159:74-9.
28. Tamura S, Hosoi H, Kuwahara Y, et al. Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun 2007;358:226-32.
29. Rousseau-Merck MF, Versteege I, Legrand I, et al. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 1999;59:3152-6.
30. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
31. Verneris MR, Arshi A, Edinger M, et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirectly cytokine-induced killer cells. Clin Cancer Res 2005;11:4561-70.
32. Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006;12:4925-32.
33. Tse C, Brault D, Gligorov J, et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 2005;51:1093-101.
34. Konigshoff M, Wilhelm J, Bohle RM, Pingoud A, Haln M. Her-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 2003;49:219-29.
35. Millson A, Suli A, Hartung L, et al. Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn 2003;5:184-90.
36. Leah NK, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-cbl and enhancing ubiquitination of HER-2. Cancer Res 2000;60:3384-8.
37. Ben-Levy R, Patherson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 1994;13:3302-11.
38. Peles E, Lamprecht R, Ben-Lery R, Tzahar E, Yarden Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3′-kinase and its release by oncogenic activation. J Biol Chem1992;267:12266-74.
39. Pandolfi PP. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 2004;251:2337-8.
40. Mineo JF, Bordron A, Guintin-Roue I, et al. Recombinant humanized anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br J Cancer 2004;91:1195-9.
41. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996;10:258-66.
42. National Cancer Institute. Available from www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=69472. ClinicalTrials (PDQ) 2007. Accessed April 1, 2007.